Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

European Journal of Heart Failure

Volumn 17, Issue 2, 2015, Pages 169-176

  Kristensen, Søren L ^a,b   Jhund, Pardeep S ^a   Køber, Lars ^c   Preiss, David ^a   Kjekshus, John ^d   McKelvie, Robert S ^e   Zile, Michael R ^f   Anand, Inder S ^g   Wikstrand, John ^h   Wedel, Hans ⁱ   Komajda, Michel ^j   Carson, Peter E ^k   Cleland, John G F ^l   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF OSLO   (Norway)

^e MCMASTER UNIVERSITY   (Canada)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^j SORBONNE UNIVERSITÉ   (France)

^k GEORGETOWN UNIVERSITY   (United States)

^l ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Clinical trials; Heart failure; HF PEF; HF REF; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; ROSUVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; WORSENING HEART FAILURE; COHORT ANALYSIS; HEART STROKE VOLUME; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT OUTCOME ASSESSMENT; STROKE; STROKE VOLUME;

EID: 84922987963     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.211     Document Type: Article

References (17)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596-602.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-944.
3. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4: 361-371.
4. Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, Teerlink JR, Metra M, Voors AA, Grinfeld L, Ruda M, Mareev V, Lotan C, Bloomfield DM, Fiuzat M, Givertz MM, Ponikowski P, Massie BM, O'Connor CM. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014; 16: 614-624.
5. Skali H, Pfeffer MA, Lubsen J, Solomon SD. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation 2006; 114: 2298-2303.
6. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-2126.
7. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
8. Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryden L. ATLAS investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 2001; 22: 1601-1612.
9. Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001; 22: 153-164.
10. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
11. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. I-Preserve Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
12. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G. I-Preserve Investigators. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576-585.
13. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005; 7: 1059-1069.
14. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F, CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009; 11: 281-291.
15. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4: 27-35.
16. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124: e540-e543.
17. Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA, Follath F. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 2008; 29: 413-421.